

# J Peter Donnelly

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6473184/j-peter-donnelly-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221  
papers

19,028  
citations

56  
h-index

135  
g-index

239  
ext. papers

21,372  
ext. citations

7  
avg. IF

6.08  
L-index

#	Paper	IF	Citations
221	The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 635-638	5.1	3
220	The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, S77-S78	11.6	1
219	Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. <i>Medical Mycology</i> , <b>2021</b> , 59, 126-138	3.9	11
218	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> ,	5.1	5
217	Reply to Herbrecht et al. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2774-2775	11.6	
216	Nucleic Acid Tools for Invasive Fungal Disease Diagnosis. <i>Current Fungal Infection Reports</i> , <b>2020</b> , 14, 76-88.4		6
215	Reply to Mafaciolli and Pasqualotto. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2542-2543	11.6	1
214	Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , <b>2020</b> , 26, 781.e1-781.e8	9.5	1
213	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1367-1376	11.6	607
212	The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. <i>Medical Mycology</i> , <b>2020</b> , 58, 779-788	3.9	18
211	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 3266	11.6	
210	New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2019</b> , 5,	5.6	16
209	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 532-533	5.1	3
208	Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. <i>The Cochrane Library</i> , <b>2019</b> , 9, CD009551	5.2	9
207	Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1389-1394	5.1	19
206	Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1131-1138	4.4	12
205	Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips. <i>Medical Mycology</i> , <b>2018</b> , 56, 60-72	3.9	30

204	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3221-3230	5.1	112
203	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authorsTresponse. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1266-1268	5.1	7
202	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2359-2367	5.1	50
201	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. <i>Medical Mycology</i> , <b>2017</b> , 55, 402-413	3.9	19
200	Issues in antifungal stewardship: an opportunity that should not be lost. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 969-974	5.1	11
199	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2397-404	5.1	145
198	How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 179-89	4.5	22
197	Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 179-82	4.7	24
196	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 960-6	9.7	17
195	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2386-96	5.1	132
194	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1293-303	11.6	130
193	Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 324-31	11.6	96
192	Analytical Comparison of In Vitro-Spiked Human Serum and Plasma for PCR-Based Detection of <i>Aspergillus fumigatus</i> DNA: a Study by the European <i>Aspergillus</i> PCR Initiative. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 2838-45	9.7	34
191	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , <b>2015</b> , 21-22, 30-40	23.2	210
190	Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 713-20	11.6	62
189	Infections in the Immunocompromised Host <b>2015</b> , 3384-3394.e2		3
188	Clinical Performance of <i>Aspergillus</i> PCR for Testing Serum and Plasma: a Study by the European <i>Aspergillus</i> PCR Initiative. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 2832-7	9.7	89
187	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1166-74	5.1	18

186	Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 264-9	4.4	13
185	Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 8-10	4.4	10
184	Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , <b>2014</b> , 16, 279-85	2.7	45
183	Long-term health related quality of life following intensive care during treatment for haematological malignancies. <i>PLoS ONE</i> , <b>2014</b> , 9, e87779	3.7	12
182	Host impairments in patients with neoplastic diseases. <i>Cancer Treatment and Research</i> , <b>2014</b> , 161, 1-41	3.5	7
181	Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1621-7	3.9	40
180	Triggers for driving treatment of at-risk patients with invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68 Suppl 3, iii17-iii24	5.1	14
179	Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2403-5	9.7	21
178	A multidisciplinary approach to managing invasive fungal disease. Introduction and aims. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68 Suppl 3, iii3-4	5.1	1
177	Role of the mycobiome in human acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 329-32	4.7	73
176	The end of the road for empirical antifungal treatment?. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 470-2	25.5	4
175	Care pathways for managing invasive mould diseases. <i>International Journal of Antimicrobial Agents</i> , <b>2013</b> , 42, 5-9	14.3	1
174	Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. <i>Bone Marrow Transplantation</i> , <b>2013</b> , 48, 977-81	4.4	27
173	Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , <b>2013</b> , 48, 1465-71	4.4	53
172	Software for dosage individualization of voriconazole for immunocompromised patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 1888-94	5.9	33
171	An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1655-9	5.1	19
170	Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 794-802	11.6	150
169	<sup>18</sup> F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 120-8	8.8	40

168	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 53-67	9.5	241
167	Towards a standard for Aspergillus PCR - requirements, process and results. <i>Infectio</i> , <b>2012</b> , 16, 64-72	0.7	4
166	Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder?. <i>Cytotherapy</i> , <b>2012</b> , 14, 381-3	4.8	5
165	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 1-8	9.5	67
164	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 9-18	9.5	239
163	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 19-37	9.5	774
162	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 38-52	9.5	206
161	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18 Suppl 7, 68-77	9.5	63
160	Three major achievements of the Infections Disease Group. <i>European Journal of Cancer, Supplement</i> , <b>2012</b> , 10, 88-93	1.6	
159	The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. <i>Journal of Oral Pathology and Medicine</i> , <b>2012</b> , 41, 229-34	3.3	24
158	Standardization of Aspergillus PCR diagnosis. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 299-300	4.4	9
157	Deferasirox as adjunctive therapy for mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 519-20	5.1	15
156	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 8-32	7.5	727
155	Differences in T cell depletion and intestinal mucositis explain inconsistent effects of NOD2/CARD15 polymorphisms in SCT. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 1421-3	4.7	6
154	Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy. <i>Medical Mycology</i> , <b>2011</b> , 49, 848-55	3.9	20
153	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. <i>Mycoses</i> , <b>2011</b> , 54, e449-55	5.2	38
152	Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 681-97	4.5	33
151	How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient. <i>European Journal of Cancer Care</i> , <b>2011</b> , 20, 679-85	2.4	7

150	European expert opinion on the management of invasive candidiasis in adults. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17 Suppl 5, 1-12	9.5	51
149	EUCAST technical note on posaconazole. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17, E16-7	9.5	13
148	EUCAST technical note on anidulafungin. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17, E18-20	9.5	50
147	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. <i>Current Fungal Infection Reports</i> , <b>2011</b> , 5, 128-134	1.4	5
146	Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients. <i>Current Opinion in Infectious Diseases</i> , <b>2011</b> , 24, 554-63	5.4	13
145	Evaluation of Aspergillus PCR protocols for testing serum specimens. <i>Journal of Clinical Microbiology</i> , <b>2011</b> , 49, 3842-8	9.7	126
144	Introduction and aims. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, i3-i4	5.1	1
143	Issues in genetic association studies: limitations of statistical analysis and biological plausibility. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 906-7	4.4	5
142	Mucosal Barrier Injury and Infections <b>2011</b> , 167-173		4
141	Infection Prevention [Protected Environment and Infection Control <b>2011</b> , 541-550		1
140	Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 107-13	5.1	34
139	Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1706-1711	10.3	52
138	Galactomannan detection and diagnosis of invasive aspergillosis. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1070-1; author reply 1071-2	11.6	17
137	Host-microbe interactions in stem cell transplantation: recognizing Candida in infection and inflammation. <i>Virulence</i> , <b>2010</b> , 1, 180-4	4.7	4
136	Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 3753-5	9.7	81
135	Aspergillus PCR: one step closer to standardization. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 1231-40	9.7	224
134	Continuous non-invasive monitoring of the skin temperature of HSCT recipients. <i>Supportive Care in Cancer</i> , <b>2010</b> , 18, 37-42	3.9	7
133	The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. <i>Clinical Immunology</i> , <b>2010</b> , 136, 302-6	9	33

132	EUCAST breakpoints for antifungals. <i>Drug News and Perspectives</i> , <b>2010</b> , 23, 93-7		34
131	Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. <i>PLoS ONE</i> , <b>2010</b> , 5, e15156	3.7	71
130	Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy?. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1052-4	11.6	16
129	Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. <i>Annals of Oncology</i> , <b>2009</b> , 20, 337-42	10.3	39
128	Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 724-32	11.6	204
127	Association of fluconazole pharmacodynamics with mortality in patients with candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2704-5; author reply 2705-6	5.9	7
126	Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1628-9	5.9	48
125	Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). <i>BMC Medicine</i> , <b>2009</b> , 7, 44	11.4	69
124	Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 387-92	3.2	51
123	A review of quality assessment of the methodology used in guidelines and systematic reviews on oral mucositis. <i>Journal of Clinical Nursing</i> , <b>2009</b> , 18, 3-12	3.2	10
122	Febrile mucositis in haematopoietic SCT recipients. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 43, 55-60	4.4	54
121	NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 243-8	4.4	53
120	Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 495-507	4.4	64
119	Safe living after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 509-19	4.4	34
118	Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. <i>Clinical Microbiology and Infection</i> , <b>2009</b> , 15, 380-6	9.5	25
117	Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 64, 408-15	2.9	28
116	Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , <b>2009</b> , 9, 89-96	25.5	272
115	Defining Invasive Aspergillosis: What the Revised EORTC/MSG Definitions Have in Store <b>2009</b> , 423-435		

114	Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 42, 345-9	4.4	37
113	EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. <i>Clinical Microbiology and Infection</i> , <b>2008</b> , 14, 398-405	9.5	348
112	EUCAST Technical Note on voriconazole. <i>Clinical Microbiology and Infection</i> , <b>2008</b> , 14, 985-7	9.5	47
111	The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , <b>2008</b> , 10, 80-9	2.7	11
110	Providing oral care in haematological oncology patients: nurses knowledge and skills. <i>European Journal of Oncology Nursing</i> , <b>2008</b> , 12, 291-8	2.8	10
109	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1813-24	11.6	3744
108	Human platelets attenuate <i>Aspergillus</i> species via granule-dependent mechanisms. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1243-6	7	56
107	Improved detection of circulating <i>Aspergillus</i> antigen by use of a modified pretreatment procedure. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 1391-7	9.7	18
106	Therapeutic drug monitoring of voriconazole. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 403-11	3.2	107
105	Challenges and progress in setting a standard for PCR for invasive aspergillosis. <i>Current Fungal Infection Reports</i> , <b>2008</b> , 2, 232-236	1.4	1
104	Determining mucosal barrier injury to the oesophagus using CT scan. <i>Supportive Care in Cancer</i> , <b>2007</b> , 15, 1105-8	3.9	6
103	Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3599-604	5.9	104
102	Optimization of the cutoff value for the <i>Aspergillus</i> double-sandwich enzyme immunoassay. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 1329-36	11.6	149
101	Prophylaxis and aspergillosis--has the principle been proven?. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 409-11	59.2	111
100	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 385-93	5.1	14
99	Statistical analyses of correlation between fluconazole MICs for <i>Candida</i> spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 109-11	9.7	43
98	Halo sign and improved outcome. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 1666-7; author reply 1667-8	11.6	13
97	Reply to Miceli and Anaissie. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 760-761	11.6	3



96	Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. <i>Annals of Hematology</i> , <b>2006</b> , 85, 621-3	3	26
95	Consensus definitions for invasive fungal disease: Strengths, limitations, and revisions. <i>Medical Mycology</i> , <b>2006</b> , 44, S285-S288	3.9	16
94	Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 4096-102	5.9	56
93	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 1031-9	11.6	2
92	Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, e23-5	11.6	40
91	A scoring system for the assessment of oral mucositis in daily nursing practice. <i>European Journal of Cancer Care</i> , <b>2006</b> , 15, 228-34	2.4	19
90	Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 38, 521-5	4.4	19
89	Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 35, 707-11	4.4	47
88	Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 36, 703-7	4.4	57
87	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. <i>Cancer</i> , <b>2005</b> , 103, 191-9	6.4	127
86	A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 790-6	3.9	34
85	Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 32-8	2.9	142
84	Validating PCR for detecting invasive aspergillosis. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 235-6	4.5	10
83	Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. <i>Clinical Microbiology and Infection</i> , <b>2004</b> , 10 Suppl 1, 107-17	9.5	74
82	Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 34, 193-6	4.4	86
81	Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. <i>Leukemia</i> , <b>2004</b> , 18, 276-84	10.7	52
80	Measuring mucosal damage induced by cytotoxic therapy. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 227-33	3.9	46
79	Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. <i>Cancer</i> , <b>2004</b> , 100, 1995-2025	6.4	1000

78	Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. <i>Lancet Infectious Diseases, The</i> , <b>2004</b> , 4, 349-57	25.5	400
77	Can anything be done about oral mucositis?. <i>Annals of Oncology</i> , <b>2003</b> , 14, 505-7	10.3	19
76	Duration of antifungal treatment and development of delayed complications in patients with candidaemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2003</b> , 22, 43-8	5.3	36
75	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). <i>Clinical Microbiology and Infection</i> , <b>2003</b> , 9, 467-74	9.5	116
74	Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. <i>Clinical Microbiology and Infection</i> , <b>2003</b> , 9, i-viii	9.5	88
73	Monitoring cyclosporine using blood drawn via a central venous catheter. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 32, 1037	4.4	9
72	Antimicrobial therapy to prevent or treat oral mucositis. <i>Lancet Infectious Diseases, The</i> , <b>2003</b> , 3, 405-12	25.5	95
71	Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. <i>Transplant Infectious Disease</i> , <b>2002</b> , 4, 64-5	2.7	14
70	Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. <i>British Journal of Haematology</i> , <b>2002</b> , 117, 259-64	4.5	32
69	In vitro activities of new and conventional antifungal agents against clinical <i>Scedosporium</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 62-8	5.9	205
68	Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 7-14	11.6	2009
67	Symptoms and diagnosis of nosocomial fungal infections -- state-of-the-art. <i>European Journal of Medical Research</i> , <b>2002</b> , 7, 192-9	4.8	6
66	Regional Variations in the Further Management of Neutropenic Patients already Receiving Empirical Antimicrobial Therapy. <i>Hematology</i> , <b>2001</b> , 5, 413-20	2.2	
65	Colorimetric assay for antifungal susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , <b>2001</b> , 39, 3402-8	9.7	142
64	Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7 Suppl 4, 47-52	9.5	27
63	Reliability of clinical research on invasive fungal infections: a systematic review of the literature. <i>Medical Mycology</i> , <b>2001</b> , 39, 35-40	3.9	29
62	Infection in the neutropenic and haematopoietic stem cell transplant recipient. <i>Current Opinion in Infectious Diseases</i> , <b>2000</b> , 13, 337-342	5.4	7
61	A strategy for managing fungal infections in haematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , <b>2000</b> , 2, 88-95	2.7	4

60	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 1269-78	4.4	181
59	Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 26, 1131-2	4.4	17
58	Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. <i>Vaccine Journal</i> , <b>2000</b> , 7, 889-92		45
57	Febrile neutropenia: antifungal prophylaxis. <i>International Journal of Antimicrobial Agents</i> , <b>2000</b> , 16, 127-30	3.3	3
56	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. <i>Journal of Clinical Microbiology</i> , <b>2000</b> , 38, 2949-54	9.7	175
55	European Surveillance of Infections in Cancer Patients--ESIC. <i>Chemotherapy</i> , <b>1999</b> , 45, 237-41	3.2	4
54	Treatment of fungal infections in surgical patients using conventional antifungals. <i>Journal of Chemotherapy</i> , <b>1999</b> , 11, 494-503	2.3	5
53	European surveillance of infections and risk factors in cancer patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>1999</b> , 18, 161-3	5.3	4
52	Commentary on the MAFF technical report: a review of antimicrobial resistance in the food chain. Ministry of Agriculture Fisheries and Food. <i>International Journal of Antimicrobial Agents</i> , <b>1999</b> , 12, 63-5	14.3	2
51	Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy. <i>Infection</i> , <b>1998</b> , 26, 349-54	5.8	6
50	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1998</b> , 42, 389-92	5.1	66
49	Host impairments in patients with neoplastic diseases. <i>Cancer Treatment and Research</i> , <b>1998</b> , 96, 1-32	3.5	
48	Two strategies for managing invasive aspergillosis: a decision analysis. <i>Clinical Infectious Diseases</i> , <b>1997</b> , 25, 1148-54	11.6	45
47	Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension?. <i>Cancer Investigation</i> , <b>1997</b> , 15, 37-46	2.1	4
46	Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. <i>Annals of Hematology</i> , <b>1997</b> , 74, 143-7	3	14
45	Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. <i>Infection</i> , <b>1997</b> , 25, 86-9	5.8	66
44	Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. <i>Journal of Clinical Microbiology</i> , <b>1997</b> , 35, 257-60	9.7	167
43	Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 1332-9	7.5	38

42	Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. <i>Reviews in Medical Microbiology</i> , <b>1996</b> , 7, 105-114	1.1	21
41	High-dose itraconazole for the treatment of cerebral aspergillosis. <i>Clinical Infectious Diseases</i> , <b>1996</b> , 23, 1196-7	11.6	9
40	Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1996</b> , 37, 389-92	5.1	38
39	An open study on the safety and efficacy of fluconazole in the treatment of disseminated <i>Candida</i> infections in patients treated for hematological malignancy. <i>Annals of Hematology</i> , <b>1995</b> , 70, 83-7	3	31
38	Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1995</b> , 36, 185-200	5.1	74
37	Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. <i>Clinical Infectious Diseases</i> , <b>1995</b> , 20, 469-70	11.6	25
36	Bacterial complications of transplantation: diagnosis and treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1995</b> , 36 Suppl B, 59-72	5.1	33
35	An open study on the safety and efficacy of fluconazole in the treatment of disseminated <i>Candida</i> infections in patients treated for hematological malignancy <b>1995</b> , 70, 83		1
34	Chemoprophylaxis for the prevention of bacterial and fungal infections. <i>Cancer Treatment and Research</i> , <b>1995</b> , 79, 45-81	3.5	7
33	Limitations of box-plots in summarizing MIC data. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1994</b> , 33, 1251-52	5.1	1
32	Pre-emptive administration of corticosteroids prevents the development of ARDS associated with <i>Streptococcus mitis</i> bacteremia following chemotherapy with high-dose cytarabine. <i>Annals of Hematology</i> , <b>1994</b> , 69, 69-71	3	19
31	Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. <i>Infection</i> , <b>1994</b> , 22, 81-5	5.8	50
30	Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. <i>Annals of Internal Medicine</i> , <b>1994</b> , 120, 834-44	8	161
29	Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11, 353-8	1.9	80
28	Potential sites of infection that develop in febrile neutropenic patients. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 10, 461-7	1.9	20
27	Empiric treatment of localized infections in the febrile neutropenic patient with monotherapy. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 9, 193-203	1.9	10
26	Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1993</b> , 25, 43-50		37
25	Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1993</b> , 31, 813-29	5.1	26

24	Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. <i>Clinical Infectious Diseases</i> , <b>1993</b> , 16, 734-5	11.6	14
23	Describing and comparing in-vitro antimicrobial activity by the box-plot technique. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1992</b> , 30, 713-9	5.1	9
22	Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group. <i>Chemotherapy</i> , <b>1992</b> , 38 Suppl 1, 43-9	3.2	38
21	High-dose meropenem in meningitis due to Pseudomonas aeruginosa. <i>Lancet, The</i> , <b>1992</b> , 339, 1117	4.0	18
20	Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 873-8	7.5	51
19	A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. <i>Bone Marrow Transplantation</i> , <b>1992</b> , 9, 409-13	4.4	55
18	Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. <i>Annals of Hematology</i> , <b>1991</b> , 63, 195-200	3	12
17	Assessment and reporting of clinical trials of empirical therapy in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1991</b> , 27, 377-87	5.1	13
16	Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1991</b> , 35, 672-8	5.9	50
15	Options and limitations of teicoplanin in febrile granulocytopenic patients. <i>British Journal of Haematology</i> , <b>1990</b> , 76 Suppl 2, 1-5	4.5	20
14	Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1990</b> , 25, 985-93	5.1	21
13	Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , <b>1990</b> , 5, 179-82	4.4	23
12	Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. <i>Netherlands Journal of Medicine</i> , <b>1990</b> , 37, 111-9	0.5	8
11	Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia. <i>Netherlands Journal of Medicine</i> , <b>1989</b> , 35, 143-6	0.5	5
10	Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. <i>Bone Marrow Transplantation</i> , <b>1988</b> , 3, 509-12	4.4	8
9	Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. <i>Journal of Infection</i> , <b>1986</b> , 13, 125-31	18.9	13
8	Comparison of methods for the interpretation of disk diffusion susceptibility tests for augmentin. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1986</b> , 5, 255-63	2.9	
7	Ceftazidime as first-line therapy for fever in acute leukaemia. <i>Journal of Infection</i> , <b>1985</b> , 11, 205-15	18.9	30

6	Bacteraemia and Hickman catheters. <i>Lancet, The</i> , <b>1985</b> , 2, 48	40	3
5	Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. <i>Journal of Hospital Infection</i> , <b>1984</b> , 5, 83-91	6.9	48
4	Serum C-reactive protein levels in the management of infection in acute leukaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1984</b> , 20, 319-25		29
3	Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. <i>Lancet, The</i> , <b>1983</b> , 2, 1452-4	40	138
2	Supportive Care in the Management of Leukaemia463-482		
1	Supportive Care in the Management of Leukaemia586-602		